References
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
- Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. Sep 15 doi:10.1182/blood.2022015850
- Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; Mar 197(3):352–372. doi:10.1002/ajh.26455
- Kaddu S, Zenahlik P, Beham-Schmid C, et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol. 1999;40(6 Pt 1):966–978. doi:10.1016/s0190-9622(99)70086-1
- Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006;47(12):2527–2541. doi:10.1080/10428190600967196
- Hoversten K, Vallapureddy R, Lasho TL, et al. Extramedullary manifestations in world health organization-defined chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Blood. 2017;130(Suppl. 1):4272–4272.
- Pudasainee P, Pyakuryal B, Subedi Y, et al. Extramedullary manifestations of chronic myelomonocytic leukemia: do we treat like an acute myeloid leukemia? Case Rep Hematol. 2019 Nov 30;2019:8360454.
- Bewersdorf JP, Zeidan AM. Risk-Adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Cancers. 2021;13(7):1610. doi:10.3390/cancers13071610
- Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452
- Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–3015. doi:10.1182/blood-2012-08-452938
- Elena C, Galli A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–1417. doi:10.1182/blood-2016-05-714030
- Montalban-Bravo G, Hammond D, DiNardo CD, et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021;35(5):1494–1499. doi:10.1038/s41375-021-01240-2
- Smith R, Mohamed B, Nettleton J. Myeloid sarcoma of the bladder in a patient with chronic myelomonocytic leukaemia: a case report and literature review. J Endolum Endourol. 2022;4(3):e36–e43. doi:10.22374/jeleu.v4i3.132
- Kwon J. Diagnosis and treatment of chronic myelomonocytic leukemia. Blood Res. 2021;56(S1):S5–S16. doi:10.5045/br.2021.2020321
- Qiao Y, Jian J, Deng L, et al. Leukaemia cutis as a specific skin involvement in chronic myelomonocytic leukaemia and review of the literature: acknowledgments. Transl Cancer Res. 2020;9(8):4988–4998. Augdoi:10.21037/tcr-19-2882